BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Nature Medicine

• Publication date

  2020-05-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41591-020-0880-xPMID 32451495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

  2020cited by this paper
• A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

  2019cited by this paper
• Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

  2019cited by this paper
• Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

  2019cited by this paper
• Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer

  2019cited by this paper
• Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.

  2019cited by this paper
• NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

  2019cited by this paper
• CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.

  2018cited by this paper
• CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.

  2018cited by this paper
• Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

  2018cited by this paper
• Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

  2018cited by this paper
• CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.

  2018cited by this paper
• Combining DNA damaging therapeutics with immunotherapy: more haste, less speed

  2017cited by this paper
• The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

  2017cited by this paper
• Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells

  2017cited by this paper
• Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

  2017cited by this paper
• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

  2016cited by this paper
• Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4

  2015cited by this paper
• Challenges and recommendations

  2015cited by this paper
• Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue

  2013cited by this paper
• Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

  2013cited by this paper
• The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

  2013cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.

  2012cited by this paper
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

  2010cited by this paper
• The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation

  2009cited by this paper
• Immunological aspects of cancer chemotherapy

  2008cited by this paper
• Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003

  2007cited by this paper
• T140 analogs as CXCR4 antagonists identified as anti‐metastatic agents in the treatment of breast cancer

  2003cited by this paper
• Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.

  2003cited by this paper
• More haste, less speed

  1990cited by this paper

• Targeting Myeloid-Derived Suppressor Cells: A Promising Strategy for Cancer Treatment

  2026cites this paper
• CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

  2026cites this paper
• Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance

  2026cites this paper
• Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells

  2026cites this paper
• CXCR4: A Promising Novel Strategy for Lung Cancer Treatment.

  2026cites this paper
• The broad spectrum of cancer and immunotherapy: achievements and limitations

  2026cites this paper
• Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

  2026cites this paper
• Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip

  2026cites this paper
• EPI-X4 is a peptide antagonist of CXCR4 with therapeutic prospects for cancer and inflammatory disorders.

  2026cites this paper
• Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.

  2026cites this paper
• Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies

  2026cites this paper
• Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies

  2026cites this paper
• Heterogeneous neutrophils: Key players in regulating tumor immunity.

  2026cites this paper
• Cytokine circuitry in pancreatic cancer: Targets for overcoming immune checkpoint inhibitor resistance in PDAC.

  2026cites this paper
• Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions.

  2026cites this paper
• Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.

  2026cites this paper
• Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.

  2025cites this paper
• Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention

  2025cites this paper
• Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer

  2025cites this paper
• Turning cold tumors into hot tumors to ignite immunotherapy

  2025cites this paper
• Insights into the relevance of targeting fibroblasts to control cancer

  2025cites this paper
• SIDISH integrates single-cell and bulk transcriptomics to identify high-risk cells and guide precision therapeutics through in silico perturbation

  2025cites this paper
• Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer

  2025cites this paper
• Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience.

  2025cites this paper
• An inherent T cell-activating mRNA delivery platform for in vivo CAR T generation

  2025cites this paper
• Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment

  2025influential citation
• ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer.

  2025cites this paper
• Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications

  2025influential citation
• Tumor microenvironment subtyping in pancreatic ductal adenocarcinoma: New avenues for personalized therapeutic strategies.

  2025cites this paper
• A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages

  2025influential citation
• Dynamic crosstalk between tumor-associated macrophages and cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.

  2025cites this paper
• Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting

  2025influential citation
• Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities

  2025cites this paper
• Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview

  2025cites this paper
• Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer

  2025cites this paper
• CXCL12 expression and the survival of patients with gastric cancer: a meta-analysis

  2025cites this paper
• Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis

  2025cites this paper
• Emerging Advancements in Metabolic Properties of Macrophages within Disease Microenvironment for Immune Therapy

  2025cites this paper
• The role of SPP1+TAMs in cancer: Impact on patient prognosis and future therapeutic targets

  2025cites this paper
• Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.

  2025cites this paper
• Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review

  2025cites this paper
• Multifaceted role of myeloid-derived suppressor cells in colorectal cancer.

  2025cites this paper
• Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine.

  2025cites this paper
• Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors

  2025cites this paper
• Perineural invasion and the “cold” tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities

  2025cites this paper
• Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques

  2025cites this paper
• The Landmark Series: The Future of Pancreatic Cancer Clinical Trials

  2025cites this paper
• The progress and perspective of nanomedicine in modulating the tumor immune microenvironment

  2025cites this paper
• Lymphatic metastasis in pancreatic cancer: from bedside to bench and back

  2025cites this paper
• Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natural killer cells in pancreatic cancer.

  2025cites this paper
• Regulatory T cells in liver metastases: emerging and divergent roles in tumour progression

  2025cites this paper
• Metastatic microenvironment of extrahepatic cholangiocarcinoma.

  2025cites this paper
• The Effect of T Regulatory Cell Infiltration on Survival Outcomes in Metastatic Pancreatic Cancer Patients with a Review of Immunobiology, Prognostic Value and Future Therapeutic Options

  2025cites this paper
• DYRK1A regulates cancer cell and cancer-associated fibroblast secretomes to foster an immunosuppressive microenvironment in pancreatic cancer

  2025cites this paper
• Targeting the chemokine receptor CXCR4 for cancer therapies

  2025cites this paper
• Deciphering of intra‐tumoural heterogeneity and the interplay between metastasis‐associated meta‐program and myofibroblasts in gastric cancer

  2025cites this paper
• The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma: Recent Advancements and Emerging Therapeutic Strategies

  2025cites this paper
• Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis

  2025cites this paper
• Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment

  2025cites this paper
• Overcoming cancer treatment resistance: Unraveling the role of cancer-associated fibroblasts

  2025cites this paper
• Chemokines and their receptors in the esophageal carcinoma tumor microenvironment: key factors for metastasis and progression

  2025cites this paper
• Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma revisited - Exploring the "Space".

  2025cites this paper
• Bystander Expression of Atypical Chemokine Receptor 2 Protects T Cells from Chemoattraction towards Cancer‐Associated Fibroblasts

  2025cites this paper
• Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms

  2025cites this paper
• Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer

  2025cites this paper
• Regulation of CXCR4 function by S1P1 through heteromerization

  2025cites this paper
• The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer

  2025cites this paper
• State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review

  2025cites this paper
• A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis

  2025cites this paper
• Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer

  2025influential citation
• DOCK9 as a predictive biomarker linked to angiogenesis and immune response in esophageal squamous cell carcinoma

  2025cites this paper
• CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer

  2025cites this paper
• Tissue mechanics in tumor heterogeneity and aggression

  2025cites this paper
• Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers

  2025cites this paper
• The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models.

  2025cites this paper
• A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer

  2025cites this paper
• Decoding the Metabolic-Immune Axis: Neutrophil Glycolysis-Driven Tumor Niche Remodeling and Its Therapeutic Exploitation.

  2025cites this paper
• MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer

  2025cites this paper
• Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer

  2025cites this paper
• A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.

  2025cites this paper
• Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention

  2025cites this paper
• Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets

  2025cites this paper
• Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications

  2025cites this paper
• Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming

  2025cites this paper
• Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention

  2025cites this paper
• Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

  2025cites this paper
• Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB signaling axis

  2025cites this paper
• Targeting immune microenvironment in cervical cancer: current research and advances

  2025cites this paper
• Classic versus innovative strategies for immuno-therapy in pancreatic cancer.

  2025cites this paper
• The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer.

  2025cites this paper
• Inhibiting cancer metastasis with water-solubilized membrane receptor CXCR4QTY-Fc as a molecular trap.

  2025cites this paper
• Domestication and feedback: bidirectional hijacking in pancreatic ductal adenocarcinoma microenvironment

  2025cites this paper
• Functional Peptides in Targeted Cancer Therapy: Mechanisms, Delivery Strategies, and Clinical Perspectives

  2025cites this paper
• Adaptations of neutrophils in cancer.

  2025cites this paper
• Signal peptide-independent secretion of keratin-19 by pancreatic cancer cells

  2025cites this paper
• The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities

  2025cites this paper
• Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis

  2025cites this paper
• Recent advances in nanoparticles-based sonodynamic and immune checkpoint blockade synergistic therapy for pancreatic ductal adenocarcinoma

  2025cites this paper
• Elevated SAMD3 expression in T cells predicts improved survival in pancreatic ductal adenocarcinoma patients

  2025cites this paper